Spotlight on HER2-Positive Gastric Cancer: Using Biomarker Testing to Inform Treatment Decisions ...

Spotlight on HER2-Positive Gastric Cancer: Using Biomarker Testing to Inform Treatment Decisions  AstraZeneca

Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line tr...

Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer  AstraZeneca

Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small ...

Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer  AstraZeneca

Tezspire approved in the US for chronic rhinosinusitis with nasal polyps - AstraZeneca

Tezspire approved in the US for chronic rhinosinusitis with nasal polyps  AstraZeneca

FLUMIST® (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now av...

FLUMIST® (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now available for home delivery  AstraZeneca

Tezspire recommended for approval in the EU by CHMP for chronic rhinosinusitis with nasal polyps ...

Tezspire recommended for approval in the EU by CHMP for chronic rhinosinusitis with nasal polyps  AstraZeneca

Trixeo Aerosphere approved in the UK as first inhaled respiratory medicine using next-generation ...

Trixeo Aerosphere approved in the UK as first inhaled respiratory medicine using next-generation propellant with near-zero Global Warming Potential  AstraZeneca

Calquence plus chemoimmunotherapy approved in the US for patients with previously untreated mantl...

Calquence plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma  AstraZeneca

Exploring the genome to find novel targets for chronic diseases - AstraZeneca

Exploring the genome to find novel targets for chronic diseases  AstraZeneca

AstraZeneca announces collaboration and investment agreement with Cellectis to accelerate cell th...

AstraZeneca announces collaboration and investment agreement with Cellectis to accelerate cell therapy and genomic medicine ambitions  AstraZeneca

Soliris approved in China for the treatment of adults with refractory generalised myasthenia grav...

Soliris approved in China for the treatment of adults with refractory generalised myasthenia gravis  AstraZeneca

Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumour...

Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours  AstraZeneca

Camizestrant demonstrated highly statistically significant and clinically meaningful improvement ...

Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 Phase III trial  AstraZeneca

AstraZeneca to acquire CinCor Pharma to strengthen cardiorenal pipeline - AstraZeneca

AstraZeneca to acquire CinCor Pharma to strengthen cardiorenal pipeline  AstraZeneca

AstraZeneca establishes new world-class functional genomics laboratory with Medical Research Coun...

AstraZeneca establishes new world-class functional genomics laboratory with Medical Research Council and the Milner Therapeutics Institute at the University of Cambridge to accelerate drug discovery and further UK’s global genomics leadership  AstraZeneca

Enhertu plus pertuzumab demonstrated highly statistically significant and clinically meaningful i...

Enhertu plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2-positive metastatic breast cancer  AstraZeneca

Acquisition of Icosavax Completed - AstraZeneca

Acquisition of Icosavax Completed  AstraZeneca

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 20...

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio  AstraZeneca

Imfinzi is first and only immunotherapy to show survival benefit in limited-stage small cell lung...

Imfinzi is first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo  AstraZeneca

Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of pro...

Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes  AstraZeneca

North Korean hackers suspected of targeting vaccine maker AstraZeneca in cyberattack, Reuters rep...

North Korean hackers suspected of targeting vaccine maker AstraZeneca in cyberattack, Reuters reports  CNN

AstraZeneca enters commercialisation agreement with Aspen for anaesthetic medicines portfolio - A...

AstraZeneca enters commercialisation agreement with Aspen for anaesthetic medicines portfolio  AstraZeneca

Koselugo (selumetinib) approved in US for paediatric patients with neurofibromatosis type 1 plexi...

Koselugo (selumetinib) approved in US for paediatric patients with neurofibromatosis type 1 plexiform neurofibromas  AstraZeneca

Biopharma leaders unite to stand with science - AstraZeneca

Biopharma leaders unite to stand with science  AstraZeneca

AstraZeneca withdraws Covid vaccine worldwide after admitting it can cause rare blood clots - The...

AstraZeneca withdraws Covid vaccine worldwide after admitting it can cause rare blood clots  The Independent

FDA approves new medicine BRILINTA (ticagrelor) for use in the US - AstraZeneca

FDA approves new medicine BRILINTA (ticagrelor) for use in the US  AstraZeneca

アストラゼネカ社ワクチン 使用中止の会見中に担当者が倒れる | TBS NEWS DIG (39QldzptPOZ) - folha do es

アストラゼネカ社ワクチン 使用中止の会見中に担当者が倒れる | TBS NEWS DIG (39QldzptPOZ)  folha do es